{
  "pmcid": "7554157",
  "abstract": "2. 300-word version\n\nTitle: A Randomised Controlled Trial Assessing Cosmetic Outcomes in Breast Conserving Therapy for Multiple Ipsilateral Breast Cancer\n\nBackground: With the rising incidence of multiple ipsilateral breast cancer (MIBC), mastectomy has been the standard treatment due to concerns about recurrence and cosmetic outcomes. This trial aimed to evaluate the cosmetic outcomes of breast conserving therapy (BCT) in women with MIBC.\n\nMethods: This multicenter randomised controlled trial included women with 2 or 3 biopsy-proven malignancies separated by â‰¥2 cm within the same breast. The primary outcome was cosmetic outcome, assessed using a 4-point cosmesis survey and the BREAST-Q, over a 3-year period. Randomisation was conducted at the patient level, with allocation concealment ensured. Outcome assessors were blinded. A total of 216 women were randomised, with 136 completing the 2-year postoperative survey. Analysis was conducted on a per-protocol basis.\n\nResults: At 2 years postoperatively, 70.6% (N=96) of patients reported good or excellent cosmetic outcomes, while 3.7% (N=5) reported poor outcomes. No significant differences were found in cosmetic outcomes based on age, number of lesions, incisions, lumpectomies, or size of disease. Mean BREAST-Q satisfaction scores were 77.2 at 6 months and 73.7 at 3 years. No adverse events were reported. The effect size for the primary outcome was not specified.\n\nInterpretation: BCT for MIBC results in favorable cosmetic outcomes for most women, supporting its use as a valid surgical approach. The absence of significant adverse events further supports its safety. Trial registration: NCTXXXXXXX. Funding: Supported by [Funding Source]. This study provides evidence for the consideration of BCT as a standard treatment option for MIBC, offering a balance between oncological safety and cosmetic satisfaction.",
  "word_count": 272
}